Key result
Emerging treatments including cardiac myosin inhibitors and gene therapies show promise for managing HCM.
Why the study?
Conventional therapies for hypertrophic cardiomyopathy focus primarily on symptomatic relief and often have limited efficacy, while multiple novel therapeutic domains have recently emerged.
Design
Review
Loading...
May shift HCM care toward targeted therapies; leaves open optimal use and long-term outcomes pending further trials.
This review highlights recent advances in HCM therapeutics, including novel pharmacological agents and liberalized exercise guidelines, which may improve patient outcomes.
A 2026 study conducted a review in Hypertrophic cardiomyopathy (HCM). Novel HCM treatment approaches (cardiac myosin inhibitors, myocardial metabolic modulators, anti-fibrotic agents, gene therapies, interventional procedures) was evaluated. Emerging treatment modalities, including cardiac myosin inhibitors, gene therapies, and interventional procedures, along with optimized exercise strategies, show promising potential for HCM management.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: